Merve AYDIN, Ali ÖZTÜRK, Olkar ABDULMAJED

Investigation of antifungal, antibiofilm and antifilamentation activities of biocides against Candida isolates

Aim: This study was aimed to evaluate the antifungal, antibiofilm, and anti-filamentation activities of three commonly used biocidesagainst clinical Candida isolates.Material and Methods: The in vitro activities of benzalkonium chloride (BZC), chlorhexidine digluconate (CHX), and triclosan (TRC)were studied against three Candida (C. albicans, C. parapsilosis, and C. glabrata) isolates. The isolates were identified, using the germ tubetest, Cornmeal agar, and ID32 C (bioMerieux, France) kit. Antifungal susceptibility of these isolates was determined using the brothmicrodilution method. Antibiofilm activity of biocides were assessed with a colorimetric method based on crystal violet. The effectof biocides on the ability of C. albicans to form hyphae was examined microscopically.Results: The antifungal, antibiofilm, and anti-filamentation activities of biocides used were determined against Candida isolates.Antifungal activities of biocides against Candida isolates ranged from 1–4 µg/ml. The potent fungistatic effect of biocides tested wasdetected against Candida spp. at 1 µg/ml. All tested biocides showed good antifungal activity against Candida isolates. The results ofthe antibiofilm activity assay showed that the highest biofilm inhibition ratios were reported in BZC, CHX, and TRC (66%, 60.3%, and58%, respectively) at 16 and 32 µg/ml. The lowest biofilm inhibition ratios were reported at MIC values for each biocide between 6%and 12%. In addition, the anti-filamentation activity of biocides tested was screened against C. albicans at concentrations of 1, 2, and4 µg/ml of biocide and the inhibition rates varied from 10% to 59%.Conclusions: Important information has been obtained about the fungistatic/fungicidal, antibiofilm activities, and effects onC. albicans micromorphology of the biocides used in this study.

PDF

___

1. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010;36:1-53.
2. Sardi JCO, Scorzoni L, Bernardi T, et al. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013;62:10-24.
3. Martins N, Ferreira IC, Barros L, et al. Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia 2014;177:223- 40.
4. Taei M, Chadeganipour M, Mohammadi R. An alarming rise of non-albicans Candida species and uncommon yeasts in the clinical samples; a combination of various molecular techniques for identification of etiologic agents. BMC Res Notes 2019;12:779.
5. Juyal D, Sharma M, Pal S, et al. Emergence of nonalbicans C andida species in neonatal candidemia. N Am J Med Sci 2013;5:541-5.
6. Schaller M, Borelli C, Korting HC, et al. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 2005;48:365-77.
7. Pierce CG, Chaturvedi AK, Lazzell AL, et al. A novel small molecule inhibitor of Candida albicans biofilm formation, filamentation and virulence with low potential for the development of resistance. NPJ Biofilms Microbiomes 2015;1. pii: 15012.
8. Gulati M, Nobile CJ. Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect 2016;18:310-21.
9. Kumamoto CA. Candida biofilms. Curr Opin Microbiol 2002;5:608-11.
10. Silva S, Henriques M, Martins A, et al. Biofilms of nonCandida albicans Candida species: quantification, structure and matrix composition. Med Mycol 2009;47:681-9.
11. Cavalheiro M, Teixeira MC. Candida biofilms: threats, challenges, and promising strategies. Front Med (Lausanne) 2018;5:28.
12. Whiteway M, Bachewich C. Morphogenesis in Candida albicans. Annu Rev Microbiol 2007;61:529-53.
13. Romo JA, Pierce CG, Chaturvedi AK, et al. Development of anti-virulence approaches for Candidiasis via a novel series of small-molecule inhibitors of Candida albicans filamentation. mBio 2017;8:pii:e01991-17.
14. Chen H, Zhou X, Ren B, et al. The regulation of hyphae growth in Candida albicans. Virulence 2020;11:337- 48.
15. Lee JH, Kim YG, Gupta VK. Suppression of fluconazole resistant Candida albicans biofilm formation and filamentation by methylindole derivatives. Front Microbiol 2018;9:2641.
16. De Muynck W, De Belie N, Verstraete W. Antimicrobial mortar surfaces for the improvement of hygienic conditions. Appl Microbiol 2010;108:62-72.
17. Morrissey I, Oggioni MR, Knight D, et al. Evaluation of epidemiological cut-off values indicates that biocide resistant subpopulations are uncommon in natural isolates of clinically-relevant microorganisms. PLoS One 2014;9:e86669.
18. Maillard JY. Antimicrobial biocides in the healthcare environment: efficacy, usage, policies, and perceived problems. Ther Clin Risk Manag 2005;1:307-20.
19. Chiapetta SC, de Oliveira ÉCB, Olivier BC, et al. Intralaboratory validation, comparison and application of HPLC-UV-DAD methods for simultaneous determination of benzalkonium chloride, chlorexidine digluconate and triclosan. J Braz Chem Soc 2011;22:1913-20.
20. Gerba CP. Quaternary ammonium biocides: efficacy in application. Appl Environ Microbiol. 2015;81:464-9.
21. Merchel Piovesan Pereira B, Tagkopoulos I. Benzalkonium chlorides: uses, regulatory status, and microbial resistance. Appl Environ Microbiol 2019;85:pii: e00377-19.
22. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999;12:147-79.
23. Zorko M, Jerala R. Alexidine and chlorhexidine bind to lipopolysaccharide and lipoteichoic acid and prevent cell activation by antibiotics. J Antimicrob Chemother 2008;62:730-7.
24. Dhillon GS, Kaur S, Pulicharla R, et al. Triclosan: current status, occurrence, environmental risks and bioaccumulation potential. Int J Environ Res Public Health 2015;12:5657-84.
25. Alfhili MA, Lee MH. Triclosan: An update on biochemical and molecular mechanisms. Oxid Med Cell Longev 2019;2019:1607304.
26. Russell AD, Furr JR. Biocides: mechanisms of antifungal action and fungal resistance. Sci Prog 1996;79:27-48.
27. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved StandardThird Edition; CLSI document M27-A3. Wayne, PA: Clinical Laboratory Standards Institute; 2008.
28. Janek T, Łukaszewicz M, Krasowska A. Antiadhesive activity of the biosurfactant pseudofactin II secreted by the Arctic bacterium Pseudomonas fluorescens BD5. BMC Microbiol 2012;12:24.
29. Romo JA, Pierce CG, Chaturvedi AK, et al. Development of anti-virulence approaches for Candidiasis via a novel series of small-molecule inhibitors of Candida albicans filamentation. mBio 2017;8:e01991-17.
30. Gunaydin M, Esen S, Karadag A, et al. In vitro antimicrobial activity of Medilox® super-oxidized water. Ann Clin Microbiol Antimicrob 2014;13:29.
31. Bridier A, Briandet R, Thomas V, et al. Resistance of bacterial biofilms to disinfectants: a review. Biofouling 2011;27:1017-32.
32. Maillard JY. Antifungal activity of disinfectants. In: Fraise AP, Lambert PA, Maillard JY, eds. Russell, Hugo and Ayliffe's Principles and Practice of Disinfection, Preservation and Sterilization. 4th edition. Blackwell; 2008. p.205-13.
33. Gupta SP, Bhati M, Jhajharia K, et al. Evaluation of antimicrobial and antifungal efficacy of inter appointment intracanal medicaments against Enterococcus and Candida albicans: an in vitro study. J Int Oral Health 2015;7:97-102.
34. Serra E, Hidalgo-Bastida LA, Verran J, et al. Antifungal activity of commercial essential oils and biocides against Candida albicans. Pathogens 2018;7:E15.
35. Théraud M, Bédouin Y, Guiguen C, et al. Efficacy of antiseptics and disinfectants on clinical and environmental yeast isolates in planktonic and biofilm conditions. J Med Microbiol 2004;53:1013-8.
36. Leung CY, Chan YC, Samaranayake LP, et al. Biocide resistance of Candida and Escherichia coli biofilms is associated with higher antioxidative capacities. J Hosp Infect 2012;81:79-86.